(12) United States Patent
`Kim et al.
`
`I 1111111111111111 11111 111111111111111 11111 lllll lllll 111111111111111 11111111
`US006284 727Bl
`US 6,284,727 Bl
`Sep.4,2001
`
`(10) Patent No.:
`(45) Date of Patent:
`
`(54) PROLONGED DELIVERY OF PEPTIDES
`
`OTHER PUBLICATIONS
`
`(75)
`
`Inventors: Yesook Kim; William J. Lambert;
`Hong Qi; Robert A Gelfand; Kieran
`F. Geoghegan; Dennis E. Danley, all
`of New York, NY (US)
`
`(73) Assignee: Scios, Inc., Sunnyvale, CA (US)
`
`( *) Notice:
`
`Subject to any disclaimer, the term of this
`patent is extended or adjusted under 35
`U.S.C. 154(b) by O days.
`
`(21) Appl. No.: 08/472,349
`
`(22) Filed:
`
`Jun. 7, 1995
`
`Related U.S. Application Data
`
`( 63) Continuation of application No. 08/181,655, filed on Jan. 25,
`1994, now abandoned, which is a continuation-in-part of
`application No. 08/044,133, filed on Apr. 7, 1993, now
`abandoned.
`
`Int. Cl.7 ..................................................... A61K 38/00
`(51)
`(52) U.S. Cl. ............................................... 514/12; 530/324
`(58) Field of Search ................................ 514/12; 530/324
`
`(56)
`
`References Cited
`
`U.S. PATENT DOCUMENTS
`
`4,654,324 * 3/1987 Chance et al. ......................... 514/12
`4,857,505 * 8/1989 Ardent ..................................... 514/2
`4,985,404 * 1/1991 Mitchell ................................... 514/6
`5,118,666 * 6/1992 Habener ................................. 514/12
`5,120,712 * 6/1992 Habener ................................. 514/12
`5,175,145 * 12/1992 Cooper ..................................... 514/4
`5,424,286
`6/1995 Eng .......................................... 514/2
`5,545,618
`8/1996 Buckley et al.
`......................... 514/2
`5,574,008
`11/1996 Johnson et al. ........................ 514/12
`5,614,492
`3/1997 Habener ................................. 514/12
`5,631,224
`5/1997 Efendic .................................. 514/12
`
`FOREIGN PATENT DOCUMENTS
`
`2/1997 (DE) .
`19530865 Al
`4/1986 (EP).
`0 177 478
`11/1989 (EP) .
`0 343 696 A2
`8/1991 (EP) .
`0 442 671 A2
`3/1992 (EP) .
`0 473 268 A3
`2/1993 (EP) .
`0 526 862 Al
`10/1994 (EP) .
`0 619 322 A2
`6/1995 (EP) .
`0 658 568 Al
`9/1996 (EP) .
`0 733 644 Al
`10/1996 (FR) .
`2 732 894
`06941 * 11/1987 (WO) .............................. C07K/7/10
`WO 88/07366
`10/1988 (WO) .
`WO 90/02835
`3/1990 (WO) .
`11296 * 10/1990 (WO) .............................. C07K/7/10
`11457 * 8/1991 (WO) .............................. C07K/7/34
`WO 93/18785
`9/1993 (WO) .
`9/1993 (WO) .
`WO 93/18786
`WO 93/19175
`9/1993 (WO).
`WO 93/25579
`12/1993 (WO) .
`WO 95/05848
`3/1995 (WO) .
`3/1995 (WO) .
`WO 95/07098
`6/1995 (WO).
`WO 95/17510
`WO 95/31214
`11/1995 (WO) .
`4/1996 (WO) .
`WO 96/20005
`
`Kreymann et al, Laneef Dec. 5, 1987 p. 1300.*
`Conn's Current Therapy p. 483. (1989).*
`Remington's Pharmaceutical Sciences, 16th ed. p. 1555,
`1467, 1453, 1451, 1450, 1448, CH 91, 1980.*
`Cross et al., "Subcutaneous Absorption Kinetics And Local
`Tissue Distribution Of Interferon And Other Solutes," J.
`Pharm. Pharmacol., 1993, 45, pp. 606-609.
`Hirano et al., "Studies on the Absorption of Practically
`Water-Insolable Drugs Following Injection VIII: Compari(cid:173)
`son of the Subcutaneous Absorption Rates From Aqueous
`Suspensions in the Mouse, Rat and Rabbit," J. Pharm. Sci.,
`1993, 72(6), pp. 608-612.
`Nara et al., "A New Method for Assessment of Drug
`Absorption From Muscle: Application of a Local Perfusion
`System," J. Pharm. Pharmacol, 1991, 43, pp. 272-274.
`Dickert et al., "Absorption of NPH-Insulin from Subcuta(cid:173)
`neous Tissue: A Methodological Study in Pigs," ACTA
`Pharmacol et Toxicol, 1982, 51, pp. 30---37.
`Supersaxo et al., "Effects of Molecular Weight on the
`Lymphatic Absorption of Water-Soluble Compounds Fol(cid:173)
`lowing Subcutanous Administration," Pharmaceutical
`Research, 1990, 7(2), pp. 167-169.
`Mosjov, "Structural Requirements for Biological Activity of
`Glucagon-Like Peptide-1, " Int. J. Peptide Protein Res.,
`1992, 40, pp. 333-343.
`Suzuki et al., "Comparison of the Effects of Various C-Ter(cid:173)
`minal and N-Terminal Fragment Peptide of Glucogen-Like
`Peptide-1 or Insulin and Glucagon Release from the Isolated
`Perfused Rat Pancreas," Endocrinology, 1989, 125(6), pp.
`3109-3113.
`Kr6wczynski, Leszek, "Technologia postaci lek6w (Tech(cid:173)
`the drug
`forms)", Panstwowy Zaklad
`nology of
`Wydawnictw Lekarskich Warszawa, 1969, pp. 220,
`463-464, 490,502.
`Gennaro, Alfonso R., Chapter 23 in Remington's Pharma(cid:173)
`ceutical Sciences, 16th edition, A Osol Editor, Mack Pub(cid:173)
`lishing Company, Easton, PA, 1980, pp. 343-363.
`Gill, I. J. et al., "Cyclodextrins as protection agents against
`enhancer damage in nasal delivery systems II. Effect on in
`vivo absorption of insulin and histopathology of nasal
`membrane," European Journal of Pharmaceutical Sciences
`1:237-248, Jun. 1994.
`Hendrick, G.K. et al., "Glucagon-like Peptide-I---(7-37)
`Suppresses Hyperglycemia in Rats," Metabolism 42(1):1-6,
`Jan. 1993.
`
`(List continued on next page.)
`
`Primary Examiner-Sheela Huff
`(74) Attorney, Agent, or Firm-Sterne, Kessler, Goldstein
`& Fox P.L.L.C.
`
`(57)
`
`ABSTRACT
`
`There are disclosed methods for the treatment of non-insulin
`dependent diabetes mellitus in a mammal comprising the
`prolonged administration of GLP-1 (7-37), and related
`peptides. Also disclosed are compositions to prolong the
`administration of the peptides.
`
`37 Claims, 10 Drawing Sheets
`
`MPI EXHIBIT 1071 PAGE 1
`
`MPI EXHIBIT 1071 PAGE 1
`
`Apotex v. Novo - IPR2024-00631
`Petitioner Apotex Exhibit 1071-0001
`
`

`

`US 6,284,727 Bl
`Page 2
`
`OIBER PUBLICATIONS
`
`Holst, J.J. et al., "Truncated glucago-like peptide I, an
`insulin-releasing hormone for the distal gut," FEES Letters
`211(2):169-174, Jan. 1987.
`Remington'Pharmaceutical Sciences, 16th ed. pp. 1555,
`1467, 1453, 1451, 1450, 1448, Ch. 91, 1980.*
`Cross et al., "Subcutaneous Absorption Kinetics and Local
`Tissue Distribution of Interferon and other Saluter," J.
`Pharm. Pharmacol., 1993, 45, pp. 606-609;.
`Hirano et al., "Studies on the Absorption of Practically
`Water-Insoluble Drugs following Injection VIII: Compari(cid:173)
`son of the Subcutaneous Absorption Rates from Aqueous
`Suspensions in the Mouse, Rat, and Rabbit," J. Pharm. Sci.,
`1993, 72(6), pp. 608-612;.
`Nara et al., "A New Method for Assessment of Drug
`Absorption from Muscle: Application of a Local Perfusion
`System," J. Pharm. Pharmacol, 1991, 43, pp. 272-274;.
`
`Dickert et al., "Absorption of NPH-Insulin from Subcuta(cid:173)
`neous Tissue: A Methodological Study in Pigs," Acta Phar(cid:173)
`macol et Toxicol, 1982, 51, pp. 30-37;.
`Supersaxo et al., "Effects of Molecular Weight on the
`Lymphatic Absorption of Water-Soluble Compounds fol(cid:173)
`lowing Subcutaneoud Administration," Pharmaceutical
`Research, 1990, 7(2), pp. 167-169;.
`Mosjov, "Structural requiremtns for Biological Activity of
`Glucagon-like Peptide-1," Int. J. Peptide Protein Res.,
`1992, 40, pp. 333-343;.
`Suzuki et al., "Comparison of the Effects of various C-Ter(cid:173)
`minal and N-Terminal Fragment Peptide of Glucogen-like
`Peptide-1 or Insulin and Glucagon Release from the Isolated
`Perfused Rat Pancreas," endocrinology, 1989, 125(6), pp.
`3109-3113.
`
`* cited by examiner
`
`MPI EXHIBIT 1071 PAGE 2
`
`MPI EXHIBIT 1071 PAGE 2
`
`Apotex v. Novo - IPR2024-00631
`Petitioner Apotex Exhibit 1071-0002
`
`

`

`U.S. Patent
`
`Sep.4,2001
`
`Sheet 1 of 10
`
`US 6,284,727 Bl
`
`"'O
`Q)
`C)
`
`C: o_
`e co
`00 a..
`II
`- -S
`II
`C:
`(1) C:
`__. LO 0
`-
`C\I ·-
`0
`-
`Cl')
`L.. LO
`:::,
`-
`C:
`0) -
`C:
`0 a..
`I
`00
`o•
`
`C
`0 ·0
`
`::J -C:
`e -0 -~
`
`C ·a.
`
`::J en
`C:
`
`,-
`
`■ c., -LL
`
`0
`CX)
`C\I
`
`0
`<.O
`C\I
`
`0
`'q"
`C\I
`
`0
`C\I
`C\I
`
`0
`0
`C\I
`
`0
`CX)
`,-
`
`0
`<.O
`,-
`
`0
`'q"
`,-
`
`0
`C\I
`,-
`
`0
`0
`,-
`
`Q)
`ca en-
`Eo=a
`cnu-
`ca :::i O>
`--E
`a_c:,_
`
`0
`C\I
`'q"
`
`0
`<.O
`(1)
`
`0
`0
`(1)
`
`0
`a:,
`,-
`
`0
`C\I ,-
`
`0
`<.O
`
`0
`
`0
`<.O
`I
`
`0
`C\I
`,-
`1
`
`MPI EXHIBIT 1071 PAGE 3
`
`MPI EXHIBIT 1071 PAGE 3
`
`Apotex v. Novo - IPR2024-00631
`Petitioner Apotex Exhibit 1071-0003
`
`

`

`U.S. Patent
`
`Sep.4,2001
`
`Sheet 2 of 10
`
`US 6,284,727 Bl
`
`-CX)
`C: -~
`
`II
`
`Q)
`E
`+:i
`ca
`Q)
`ro~
`II
`-
`C:
`('I')
`_LO
`-
`C\I
`0
`-
`L.. LO
`..... 0)
`C:
`I
`0 a.
`(.)(.)
`0
`•
`
`-.:t"
`II
`C:
`
`-.:t"
`
`I
`
`C\I
`
`■ c., -u..
`
`0
`CX)
`C\I
`
`0
`(0
`C\I
`
`0
`""""
`C\I
`
`0
`C\I
`C\I
`
`0
`0
`C\I
`
`0
`CX)
`T"""
`
`0
`(0
`T"""
`
`0
`""""
`
`T"""
`
`0
`C\I
`T"""
`
`0
`·O
`T"""
`
`Q)
`ca en-
`Eo=o
`(/) 0 O>
`~.:?E
`a. (!J .._
`
`0
`(0
`('I')
`
`0
`0
`('I')
`
`0
`"""" C\I
`
`(I)
`
`o E
`~ i=
`
`0
`(0
`
`0
`
`0
`(0
`I
`
`0
`C\I
`T"""
`I
`
`MPI EXHIBIT 1071 PAGE 4
`
`MPI EXHIBIT 1071 PAGE 4
`
`Apotex v. Novo - IPR2024-00631
`Petitioner Apotex Exhibit 1071-0004
`
`

`

`U.S. Patent
`
`Sep.4,2001
`
`Sheet 3 of 10
`
`US 6,284,727 Bl
`
`II
`
`II
`
`--CX) CX)
`'C: C: --C: C:
`E E --~~ --C) C)
`- ... , ... ,
`
`CX) C\I v
`C: C:
`-
`II Ct"J- Ct"J
`C:
`II"\
`II"\
`C\I C\I
`-
`-
`0
`'- LO CO
`0) 0)
`-
`C:
`I
`I
`0 a.. a..
`(.)(.)(.)
`
`Oe ◄
`
`■ c.:, -LL
`
`C
`0
`·en
`:::,
`
`-C
`
`C: ·a
`e
`0
`C
`::::,
`C/J
`C
`
`0 co
`C\I
`
`0
`(0
`C\I
`
`0 v
`C\I
`
`0
`C\I
`C\I
`
`0
`0
`C\I
`
`0
`CX)
`,-
`
`0
`(0
`,-
`
`0
`v
`,-
`
`0
`C\I
`, -
`
`0
`0
`, -
`
`Q) «sen-
`Eo=o
`en u -
`«s ::::JC)
`--E
`a.. (!J - -
`
`0
`C\I v
`
`0 co
`
`Ct)
`
`0
`0
`Ct)
`
`0 v
`C\I
`
`0
`CX)
`,-
`
`0
`C\I
`,-
`
`0
`(0
`
`0
`
`0
`(0
`I
`
`0
`C\I
`, -
`I
`
`MPI EXHIBIT 1071 PAGE 5
`
`MPI EXHIBIT 1071 PAGE 5
`
`Apotex v. Novo - IPR2024-00631
`Petitioner Apotex Exhibit 1071-0005
`
`

`

`U.S. Patent
`
`Sep.4,2001
`
`Sheet 4 of 10
`
`US 6,284,727 Bl
`
`-r- C\J Ct) ~ lO <O
`r-,...
`Cl) en en en en en en
`<( <( <( <( <( <( <(
`
`I t I
`t i
`+ □ ~+ 1
`: I
`i
`
`I
`
`-u.
`
`il
`
`I
`I
`I
`I
`••
`1.,.•··
`
`.l
`
`El
`
`fr ;
`j
`
`0
`C')
`
`~
`C\J
`
`-~ .c -Q)
`
`E
`F
`
`co
`
`'r"
`
`C\J
`'r"
`
`<D
`
`rrr.--ir-r--,---.-,-----r"T"""-r-,--,---r---.---r----.----1- o
`0
`T'""
`
`'r"
`
`'r"
`
`(1w/f5u}
`ewse1d u1 suo11eJiuaouo8 u1d0Jiou11nsu1
`
`MPI EXHIBIT 1071 PAGE 6
`
`MPI EXHIBIT 1071 PAGE 6
`
`Apotex v. Novo - IPR2024-00631
`Petitioner Apotex Exhibit 1071-0006
`
`

`

`U.S. Patent
`
`Sep.4,2001
`
`Sheet 5 of 10
`
`US 6,284,727 Bl
`
`C\J lO CO
`t--- a:)
`,--
`,-- ,-
`,--
`,--
`en<C cn en en en
`<( <( <( <(
`. I
`□ <;J
`'
`
`I
`I
`
`I
`I
`
`I I 6.
`I I
`
`I
`I
`I
`
`tt
`
`I
`I
`
`I
`I
`
`Lt)
`
`-LL
`
`;=:J
`
`0
`C")
`
`I
`I
`I
`I
`I
`
`<f I
`
`I
`I
`
`I
`I
`
`~
`,
`i ,'
`,
`I
`i
`I
`:
`
`,
`I
`
`• I
`
`j I JJ
`.. ~ .. ··~
`.. ,
`~
`
`-~
`.c -a>
`
`E
`i-
`
`a:)
`,--
`
`C\J
`,--
`
`rrr11r-T-r--r---,TT"1r,--,r--r~---,-----.-,1"T""1""'T"""'f"--.---.--.......... -_J_ O
`,--
`0
`,--
`,--
`,--
`0
`
`(1w/f5u)
`ewse1d u1 SUO!lBJlUeouoo U!dOJlOU!lnsu1
`
`MPI EXHIBIT 1071 PAGE 7
`
`MPI EXHIBIT 1071 PAGE 7
`
`Apotex v. Novo - IPR2024-00631
`Petitioner Apotex Exhibit 1071-0007
`
`

`

`U.S. Patent
`
`Sep.4,2001
`
`Sheet 6 of 10
`
`US 6,284,727 Bl
`
`C\I ('t) ~ LO
`C\I C\I C\I C\I
`Cf) Cl) Cf) Cf)
`<( <( <( <(
`
`ttti
`
`I
`
`•
`
`~
`! i • •
`! ' . I 9 1J
`i I
`i1J
`-~~
`: .
`.
`• I
`• •
`•
`•
`,
`I
`, ,
`,
`r;l
`~
`,
`•
`I
`• I
`,
`p~
`,•'/
`!I
`~
`4('
`
`I
`
`I
`
`I
`
`I
`
`I
`
`-r-
`
`(1w;6u)
`BWSl?ld u1 SUO!Jl:?JJU80U08 U!dOJJOU1tnsu1
`
`-r-
`
`.
`
`0
`('t)
`
`~
`C\I
`
`a:,
`
`'t- -~
`-
`
`.c
`Q)
`
`E
`i=
`
`C\I
`'t-
`
`(0
`
`0
`
`'t-
`0
`
`(.0
`
`-
`
`■
`
`C,
`u.
`
`0
`-r-
`
`MPI EXHIBIT 1071 PAGE 8
`
`MPI EXHIBIT 1071 PAGE 8
`
`Apotex v. Novo - IPR2024-00631
`Petitioner Apotex Exhibit 1071-0008
`
`

`

`U.S. Patent
`
`Sep.4,2001
`
`Sheet 7 of 10
`
`US 6,284,727 Bl
`
`0)
`C\I
`CJ)
`,c:i:
`
`t
`
`a I
`
`I
`I
`I
`
`'
`
`0
`(Y)
`
`~
`C\I
`
`-~ .c
`
`.........
`(1)
`E
`i=
`
`(X)
`,-.
`
`C\I
`,-.
`
`(0
`
`■
`
`"-
`
`(!J -u.
`
`p
`
`• • • • • • •
`d I
`' I
`I a
`
`I
`I
`
`I
`I
`
`(1w/f>u)
`l:?WSl:?ld UI SUO!ll:?JlU80UOQ u1doJJOU!lnsu1
`
`MPI EXHIBIT 1071 PAGE 9
`
`MPI EXHIBIT 1071 PAGE 9
`
`Apotex v. Novo - IPR2024-00631
`Petitioner Apotex Exhibit 1071-0009
`
`

`

`U.S. Patent
`
`Sep.4,2001
`
`Sheet 8 of 10
`
`US 6,284,727 Bl
`
`FIG. 8
`
`1000 , - - - - - - - - - - - - - - - - - - - - - - - - - - -
`
`100
`
`--e-AS51
`
`-lr-AS52
`
`-+-AS69
`
`-o-AS71
`
`(/)
`
`C:
`
`-<U
`E
`ct! a.
`E --0)
`10 -C:
`·a..
`e -0 -~
`
`::::,
`(/)
`C:
`
`1
`
`0.1 - t - - - - -y - - - - - . - - - - . - - - - - - , - - - - - - r - - - -__ J
`0
`5
`10
`15
`20
`25
`30
`Time (hours)
`
`MPI EXHIBIT 1071 PAGE 10
`
`MPI EXHIBIT 1071 PAGE 10
`
`Apotex v. Novo - IPR2024-00631
`Petitioner Apotex Exhibit 1071-0010
`
`

`

`U.S. Patent
`
`Sep.4,2001
`
`Sheet 9 of 10
`
`US 6,284,727 Bl
`
`FIG. 9
`
`100 - . - - - - - - - - - - - - - - - - - - - - - -~
`
`-11-AS53
`
`-AS64
`
`~
`E
`(/)
`ct!
`a.
`E
`oi
`C
`--
`
`C ·5. 10 . - - - - - - - - -~ - - - - - - - - - - - - - - - - - - l
`e
`0
`C
`::J
`(/)
`C
`
`1 .------.---.---.--.---,-----,,-------r--r--~-......--.,.;.._._J
`0
`5
`10
`15
`20
`25
`30
`Time (hours)
`
`MPI EXHIBIT 1071 PAGE 11
`
`MPI EXHIBIT 1071 PAGE 11
`
`Apotex v. Novo - IPR2024-00631
`Petitioner Apotex Exhibit 1071-0011
`
`

`

`U.S. Patent
`U.S. Patent
`
`Sep. 4, 2001
`Sep.4,2001
`
`Sheet 10 of 10
`Sheet 10 of 10
`
`US 6,284,727 B1
`US 6,284,727 Bl
`
`-~
`.c -Q)
`~~,
`”
`£
`@
`E
`E
`i=
`
`LO
`WwW
`C\I
`N
`
`0
`C\I
`
`©A
`
`a
`
`LO
`iO
`bo
`,-
`
`0 ,-
`©
`
`ln
`LO
`
`Oo
`
`,-.
`rT
`S
`0
`
`@
`Q)
`C ·-
`£
`C
`@
`oO
`
`||
`
`fh
`
`wn
`3
`/2
`ao.
`S
`<x
`:
`
`=ant
`O
`
`a
`
`0
`©
`, -
`=
`
`0
`©
`0 ,-
`2
`
`rT
`T"""
`
`Conc.(ng/ml)
`
`0 ,...
`©
`■ C, -LL
`
`a L
`
`L.
`
`Tf
`
`a©
`
`Apotex v. Novo - IPR2024-00631
`Petitioner Apotex Exhibit 1071-0012
`
`MPI EXHIBIT 1071 PAGE 12
`
`MPI EXHIBIT 1071 PAGE 12
`
`MPI EXHIBIT 1071 PAGE 12
`
`Apotex v. Novo - IPR2024-00631
`Petitioner Apotex Exhibit 1071-0012
`
`

`

`1
`PROLONGED DELIVERY OF PEPTIDES
`
`US 6,284,727 Bl
`
`2
`His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr(cid:173)
`Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp(cid:173)
`Leu-Val-Lys (SEQUENCE ID NO: 5);
`Derivatives of the polypeptides disclosed in PCT/US89/
`5 01121 include polypeptides having inconsequential amino
`acid substitutions, or additional amino acids to enhance
`coupling to carrier protein or to enhance the insulinotropic
`effect thereof. Further derivatives of insulinotropin disclosed
`in PCT/US89/01121 include certain C-terminal salts, esters
`10 and amides where the salts and esters are defined as OM
`where M is a pharmaceutically acceptable cation or a lower
`branched or unbranched alkyl group and the amides are
`defined as -NR2R3 where R2 and R3 are the same or
`different and are selected from the group consisting of
`15 hydrogen and a lower branched or unbranched alkyl group.
`
`20
`
`This application is a continuation of application Ser. No.
`08/181,655, filed Jan. 25, 1994, now abandoned, which is a
`continuation-in-part of application Ser. No. 08/044,133,
`filed Apr. 7, 1993, now abandoned.
`BACKGROUND OF THE INVENTION
`The present invention relates to compositions and meth(cid:173)
`ods for the treatment of Diabetes Mellitus. More specifically,
`the present invention relates to compositions to prolong the
`administration of glucagon-like peptide 1 (GLP-1), and
`derivatives thereof. These compositions are useful in treat(cid:173)
`ment of Non-Insulin Dependent Diabetes Mellitus
`(NIDDM).
`The amino acid sequence of GLP-1 is known as:
`His-Asp-Glu-Phe-Glu-Arg-His-Ala-Glu-Gly-Thr-Phe-Thr(cid:173)
`Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-
`G l u- Phe -Ile -Al a- Trp- Leu- Val-Lys-Gly-Arg-G ly
`(SEQUENCE ID NO: 1)
`GLP-1 is disclosed by Lopez, L. C., et al., P.N.A.S., USA
`80: 5485-5489 (1983); Bell, G. I., et al., Nature 302:
`716-718 (1983); Heinrich, G. et al., Endocrinol. 115:
`2176-2181 (1984) and Ghiglione, M., et al., Diabetologia
`27: 599-600 (1984).
`During processing in the pancreas and intestine, GLP-1 is 25
`converted to a 31 amino acid peptide having amino acids
`7-37 of GLP-1, hereinafter this peptide is referred to as
`GLP-1 (7-37).
`This peptide has been shown to have insulinotropic
`activity, that is, it is able to stimulate, or cause to be 30
`stimulated, the synthesis or expression of the hormone
`insulin. Because of this insulinotropic activity, GLP-1
`(7-37) is alternatively referred to as insulinotropin.
`GLP-1 (7-37) has the following amino acid sequence:
`His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr- 35
`Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp(cid:173)
`Leu-Val-Lys-Gly-Arg-Gly (SEQUENCE ID NO: 2).
`GLP-1 (7-37), certain derivatives thereof and the use
`thereof to treat Diabetes mellitus in a mammal are disclosed
`in U.S. Pat. Nos. 5,118,666 ('666 patent) and 5,120,712 40
`('712 patent), the disclosures of these patents being incor(cid:173)
`porated herein by reference. The derivatives of GLP-1
`(7-37) disclosed in the '666 and '712 patents include
`polypeptides which contain or lack one of more amino acids
`that may not be present in the naturally occurring sequence. 45
`Further derivatives of GLP-1 (7-37) disclosed in the '666
`and '712 patents include certain C-terminal salts, esters and
`amides where the salts and esters are defined as OM where
`M is a pharmaceutically acceptable cation or a lower
`(C1-C6) branched or unbranched alkyl group and the amides 50
`are defined as -NR2R3 where R2 and R3 are the same or
`different and are selected from the group consisting of
`hydrogen and a lower (CcC6) branched or unbranched alkyl
`group.
`Certain other polypeptides, alternatively referred to as
`truncated GLP-1 or truncated insulinotropin, having insuli(cid:173)
`notropic activity and the derivatives thereof are disclosed in
`PCT/US 89/01121 (WO 90/11296). Those polypeptides,
`referred to therein as GLP-1 (7-36), GLP-1 (7-35) and
`GLP-1 (7-34) have the following amino acid sequences, 60
`respectively.
`His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-
`Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp(cid:173)
`Leu-Val-Lys-Gly-Arg (SEQUENCE ID NO: 3);
`His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr- 65
`Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp(cid:173)
`Leu-Val-Lys-Gly (SEQUENCE ID NO: 4); and
`
`BRIEF DESCRIPTION OF THE DRAWINGS
`
`FIG. 1 shows the effect of a prolonged infusion (7 hours)
`of 4 ng/kg/min insulinotropin on plasma glucose levels in
`patients with NIDDM.
`FIG. 2 shows the effect of a short infusion (60 minutes)
`of 10 ng/kg/min insulinotropin on plasma glucose levels in
`patients with NIDDM.
`FIG. 3 shows the effect of a prolonged infusion (7 hours)
`of 2 ng/kg/min and 4 ng/kg/min of insulinotropin on plasma
`glucose levels in patients with NIDDM.
`FIG. 4. Mean (n=3) Plasma Concentration of Insulinotro(cid:173)
`pin in Rats After Subcutaneous Administration of Single 0.5
`mg/0.5 ml Doses in Different Aqueous Suspensions (AS).
`FIG. 5. Mean (n=3) Plasma Concentration of Insulinotro(cid:173)
`pin in Rats After Subcutaneous Administration of Single 0.5
`mg/0.5 ml Doses in Different Aqueous Suspensions (AS).
`FIG. 6. Mean (n=3) Plasma Concentration of Insulinotro(cid:173)
`pin in Rats After Subcutaneous Administration of Single 0.5
`mg/0.5 ml Doses in Different Aqueous Suspensions (AS).
`FIG. 7. Mean (n=3) Plasma Concentration of Insulinotro(cid:173)
`pin in Rats After Subcutaneous Administration of Single 0.5
`mg/0.5 ml Doses in Different Aqueous Suspensions (AS).
`FIG. 8. Mean (n=3) Plasma Concentration of Insulinotro(cid:173)
`pin in Rats After Subcutaneous Administration of Single 0.5
`mg/0.13 ml Doses in Different Aqueous Suspensions (AS).
`FIG. 9. Mean (n=3) Plasma Concentration of Insulinotro(cid:173)
`pin in Rats After Subcutaneous Administration of Single 0.5
`mg/0.13 ml Doses in Different Aqueous Suspensions (AS).
`FIG. 10 shows pharmacokinetic studies of an insulinotro(cid:173)
`pin zinc precipitate.
`
`SUMMARY OF THE INVENTION
`
`In one embodiment, the present invention is directed to a
`method for the treatment of non-insulin dependent diabetes
`mellitus in a mammal in need of such treatment comprising
`55 the repeated administration over an extended period of time
`of a compound with prolonged action after each
`administration, said prolonged action necessary to achieve
`sustained glycemic control in such mammals, said com(cid:173)
`pound selected from the group consisting of:
`(a) a peptide having the amino acid sequence:
`His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr(cid:173)
`Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp(cid:173)
`Leu-Val-Lys-Gly-Arg-Gly; (SEQUENCE ID NO: 2)
`(b) a peptide having the amino acid sequence:
`His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr(cid:173)
`Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp(cid:173)
`Leu-Val-X (SEQUENCE ID NO: 7)
`
`MPI EXHIBIT 1071 PAGE 13
`
`MPI EXHIBIT 1071 PAGE 13
`
`Apotex v. Novo - IPR2024-00631
`Petitioner Apotex Exhibit 1071-0013
`
`

`

`US 6,284,727 Bl
`
`3
`wherein X is selected from the group consisting of:
`(A) Lys,
`(B) Lys-Gly, and
`(C) Lys-Gly-Arg;
`(c) a derivative of a polypeptide comprising the primary 5
`structure
`
`10
`
`H2N-W---COOH
`wherein W is an amino acid sequence selected from the
`group consisting of
`His-Asp-Glu-Phe-Glu-Arg-His-Ala-Glu-Gly-Thr-Phe-Thr-
`Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys(cid:173)
`G l u- Phe -Ile -Al a- Trp- Leu- Val-Lys-Gly-Arg-G ly
`(SEQUENCE ID NO: 1) and
`His-Asp-Glu-Phe-Glu-Arg-His-Ala-Glu-Gly-Thr-Phe-Thr- 15
`Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-
`G 1 u-Phe -Ile-Ala-Trp-Le u- Val-Lys-G ly-Arg
`(SEQUENCE ID NO: 6)
`which derivative when processed in a mammal results in a
`polypeptide derivative having an insulinotropic activity;
`(d) a derivative of a polypeptide comprising the primary
`structure
`
`20
`
`4
`In another embodiment, the present invention is directed
`to a composition of matter comprising;
`(i) a compound selected from the group consisting of:
`(a) a peptide having the amino acid sequence:
`His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr(cid:173)
`Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp(cid:173)
`Leu-Val-Lys-Gly-Arg-Gly; (SEQUENCE ID NO: 2)
`(b) a peptide having the amino acid sequence:
`His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-
`Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-
`Leu-Val-X (SEQUENCE ID NO: 7)
`wherein X is selected from the group consisting of:
`(A) Lys,
`(B) Lys-Gly, and
`(C) Lys-Gly-Arg;
`(c) a derivative of a polypeptide comprising the primary
`structure
`
`H2N-W---COOH
`wherein W is an amino acid sequence selected from the
`group consisting of
`His-Asp-Glu-Phe-Glu-Arg-His-Ala-Glu-Gly-Thr-Phe-Thr-
`Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys(cid:173)
`G lu-Phe-Ile-Ala-Trp-Leu- Val-Lys-Gly-Arg-G ly
`(SEQUENCE ID NO: 1) and
`His-Asp-Glu-Phe-Glu-Arg-His-Ala-Glu-Gly-Thr-Phe-Thr(cid:173)
`Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys(cid:173)
`G 1 u-Phe -Ile-Ala-Trp-Le u- Val-Lys-G ly-Arg
`(SEQUENCE ID NO: 6)
`which derivative when processed in a mammal results in a
`polypeptide derivative having an insulinotropic activity;
`(d) a derivative of a polypeptide comprising the primary
`structure
`
`35
`
`40
`
`H2N-R---COOH
`wherein R is an amino acid sequence selected from the 25
`group consisting of
`His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-
`Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp(cid:173)
`Leu-Val-Lys-Gly-Arg-Gly; (SEQUENCE ID NO: 2)
`His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr- 30
`Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp(cid:173)
`Leu-Val-Lys-Gly-Arg; (SEQUENCE ID NO: 3)
`His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-
`Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-
`Leu-Val-Lys-Gly; (SEQUENCE ID NO: 4) and
`His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr(cid:173)
`Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp(cid:173)
`Leu-Val-Lys; (SEQUENCE ID NO: 5) and
`(e) a derivative of said peptides (a) through (d) wherein
`said derivative is selected from the group consisting of:
`(1) a pharmaceutically acceptable acid addition salt of
`said peptides;
`(2) a pharmaceutically acceptable carboxylate salt of said
`peptides;
`(3) a pharmaceutically acceptable alkali addition salt of
`said peptides;
`( 4) a pharmaceutically acceptable lower alkyl ester of said
`peptides; and
`(5) a pharmaceutically acceptable amide of said peptides 50
`wherein said pharmaceutically acceptable amide is
`selected from the group consisting of amide, lower
`alkyl amide and lower dialkyl amide.
`Preferred is the method wherein said administration is
`subcutaneous.
`Also preferred is the method wherein said administration
`is intramuscular.
`Also preferred is the method wherein said administration
`is transdermal.
`Also especially preferred is the method wherein said 60
`administration is by an infusion pump.
`Also preferred is the method wherein said administration
`is by oral inhalation.
`Also preferred is the method wherein said administration
`is by nasal inhalation.
`Also preferred is the method wherein said administration
`is gastrointestinal.
`
`55
`
`65
`
`H2N-R---COOH
`wherein R is an amino acid sequence selected from the
`group consisting of
`His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr(cid:173)
`Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp(cid:173)
`Leu-Val-Lys-Gly-Arg-Gly (SEQUENCE ID NO: 2)
`His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr(cid:173)
`Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp(cid:173)
`Leu-Val-Lys-Gly-Arg (SEQUENCE ID NO: 3)
`45 His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr(cid:173)
`Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp(cid:173)
`Leu-Val-Lys-Gly (SEQUENCE ID NO: 4) and
`His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr(cid:173)
`Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp(cid:173)
`Leu-Val-Lys (SEQUENCE ID NO: 5);
`a derivative of said peptides ( a) through ( d) wherein said
`derivative is selected from the group consisting of:
`(1) a pharmaceutically acceptable acid addition salt of
`said peptides;
`(2) a pharmaceutically acceptable carboxylate salt of said
`peptides;
`(3) a pharmaceutically acceptable alkali addition salt of
`said peptides;
`( 4) a pharmaceutically acceptable lower alkyl ester of said
`peptides; and
`(5) a pharmaceutically acceptable amide of said peptides
`wherein said pharmaceutically acceptable amide is
`selected from the group consisting of amide, lower
`alkyl amide and lower dialkyl amide, and
`(ii) a polymer capable of prolonging the action of said
`compound to achieve sustained glycemic control.
`
`MPI EXHIBIT 1071 PAGE 14
`
`MPI EXHIBIT 1071 PAGE 14
`
`Apotex v. Novo - IPR2024-00631
`Petitioner Apotex Exhibit 1071-0014
`
`

`

`US 6,284,727 Bl
`
`5
`Especially preferred is the compos1t10n wherein said
`polymer is a low molecular weight polymer.
`Further especially preferred is a composition wherein said
`polymer is selected from the group consisting of polyeth(cid:173)
`ylene glycol, polyvinylpyrrolidone, polyvinylalcohol, 5
`polyoxyethylene-polyoxypropylene copolymers, polysac(cid:173)
`charides selected from the group consisting of cellulose,
`cellulose derivatives, chitosan, acacia gum, karaya gum,
`guar gum, xanthan gum, tragacanth, alginic acid,
`carrageenan, agarose, and furcellarans, dextran, starch, 10
`starch derivatives, hyaluronic acid, polyesters, polyamides,
`polyanhydrides, and polyortho esters, with especially pre(cid:173)
`ferred polymers selected from the group consisting of poly(cid:173)
`ethylene glycol and polyvinylpyrrolidone.
`In another embodiment, the present invention is directed 15
`to a composition of matter comprising;
`(i) a compound selected from the group consisting of:
`(a) a peptide having the amino acid sequence:
`His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr(cid:173)
`Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp- 20
`Leu-Val-Lys-Gly-Arg-Gly (SEQUENCE ID NO: 2);
`(b) a peptide having the amino acid sequence:
`His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr(cid:173)
`Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp(cid:173)
`Leu-Val-X (SEQUENCE ID NO: 7)
`wherein X is selected from the group consisting of:
`(A) Lys,
`(B) Lys-Gly, and
`(C) Lys-Gly-Arg;
`(c) a derivative of a polypeptide comprising the primary
`structure
`
`H2N-W---COOH
`wherein W is an amino acid sequence selected from the 35
`group consisting of
`His-Asp-Glu-Phe-Glu-Arg-His-Ala-Glu-Gly-Thr-Phe-Thr-
`Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys(cid:173)
`G l u- Phe -Ile -Al a- Trp- Leu- Val-Lys-Gly-Arg-G ly
`(SEQUENCE ID NO: 1) and
`His-Asp-Glu-Phe-Glu-Arg-His-Ala-Glu-Gly-Thr-Phe-Thr(cid:173)
`Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys(cid:173)
`G 1 u-Phe -Ile-Ala-Trp-Le u- Val-Lys-G ly-Arg
`(SEQUENCE ID NO: 6)
`which derivative when processed in a mammal results in a 45
`polypeptide derivative having an insulinotropic activity;
`(d) a derivative of a polypeptide comprising the primary
`structure
`
`40
`
`6
`(1) a pharmaceutically acceptable acid addition salt of
`said peptides;
`(2) a pharmaceutically acceptable carboxylate salt of said
`peptides;
`(3) a pharmaceutically acceptable alkali addition salt of
`said peptides;
`( 4) a pharmaceutically acceptable lower alkyl ester of said
`peptides; and
`(5) a pharmaceutically acceptable amide of said peptides
`wherein said pharmaceutically acceptable amide is
`selected from the group consisting of amide, lower
`alkyl amide and lower dialkyl amide, and
`(ii) a pharmaceutically acceptable water-immiscible oil
`suspension capable of prolonging administration of
`said compound.
`Especially preferred is the composition wherein said oil is
`selected from the group consisting of peanut oil, sesame oil,
`almond oil, castor oil, camellia oil, cotton seed oil, olive oil,
`corn oil, soy oil, safflower oil, coconut oil, esters of fatty
`acids, and esters of fatty alcohols.
`Further especially preferred is the composition further
`comprising a wetting agent, especially a nonionic surfactant.
`More further especially preferred is the composition fur-
`25 ther comprising a suspending agent.
`In another embodiment, the present invention is directed
`to a composition of matter comprising;
`(i) a compound selected from the group consisting of:
`(a) a peptide having the amino acid sequence:
`30 His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr(cid:173)
`Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp(cid:173)
`Leu-Val-Lys-Gly-Arg-Gly (SEQUENCE ID NO: 2);
`(b) a peptide having the amino acid sequence:
`His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr(cid:173)
`Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp(cid:173)
`Leu-Val-X (SEQUENCE ID NO: 7)
`wherein X is selected from the group consisting of:
`(A) Lys,
`(B) Lys-Gly, and
`(C) Lys-Gly-Arg;
`(c) a derivative of a polypeptide comprising the primary
`structure
`
`H2N-W---COOH
`
`wherein W is an amino acid sequence selected from the
`group consisting of
`His-Asp-Glu-Phe-Glu-Arg-His-Ala-Glu-Gly-Thr-Phe-Thr-
`Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys(cid:173)
`G lu-Phe-Ile-Ala-Trp-Leu- Val-Lys-Gly-Arg-G ly
`(SEQUENCE ID NO: 1) and
`His-Asp-Glu-Phe-Glu-Arg-His-Ala-Glu-Gly-Thr-Phe-Thr(cid:173)
`Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys(cid:173)
`G 1 u-Phe -Ile-Ala-Trp-Le u- Val-Lys-G ly-Arg
`(SEQUENCE ID NO: 6)
`which derivative when processed in a mammal results in a
`polypeptide derivative having an insulinotropic activity;
`(d) a derivative of a polypeptide comprising the primary
`structure
`
`H2N-R---COOH
`
`H2N-R---COOH
`
`50
`
`wherein R is an amino acid sequence selected from the
`group consisting of
`His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-
`Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp- 55
`Leu-Val-Lys-Gly-Arg-Gly (SEQUENCE ID NO:2);
`His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr(cid:173)
`Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp(cid:173)
`Leu-Val-Lys-Gly-Arg (SEQUENCE ID NO: 3);
`His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr- 60
`Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp(cid:173)
`Leu-Val-Lys-Gly (SEQUENCE ID NO: 4); and
`His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr(cid:173)
`Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp(cid:173)
`Leu-Val-Lys (SEQUENCE ID NO: 5); and
`a derivative of said peptides (a) through (d) wherein said
`derivative is selected from the group consisting of:
`
`wherein R is an amino acid sequence selected from the
`group consisting of
`65 His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr(cid:173)
`Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp(cid:173)
`Leu-Val-Lys-Gly-Arg-Gly (SEQUENCE ID NO: 2)
`
`MPI EXHIBIT 1071 PAGE 15
`
`MPI EXHIBIT 1071 PAGE 15
`
`Apotex v. Novo - IPR2024-00631
`Petitioner Apotex Exhibit 1071-0015
`
`

`

`US 6,284,727 Bl
`
`5
`
`15
`
`20
`
`7
`His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr(cid:173)
`Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp(cid:173)
`Leu-Val-Lys-Gly-Arg (SEQUENCE ID NO: 3)
`His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr(cid:173)
`Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-
`Leu-Val-Lys-Gly (SEQUENCE ID NO: 4) and
`His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr(cid:173)
`Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp(cid:173)
`Leu-Val-Lys (SEQUENCE ID NO: 5); and
`a derivative of said peptides (a) through (d) wherein said 10
`derivative is selected from the group consisting of:
`(1) a pharmaceutically acceptable acid addition salt of
`said peptides;
`(2) a pharmaceutically acceptable carboxylate salt of said
`peptides;
`(3) a pharmace